Incidents of the Use of Auto-Injectable Epinephrine

(Pursuant to PA 221 of 2015, MCL 333.17744d)

December 31, 2016

Prepared by

Kimberly Gaedeke, Director

Bureau of Professional Licensing

Reporting Period: March 16, 2016 to December 31, 2016

RICK SNYDER
GOVERNOR

SHELLY EDGERTON
DIRECTOR

Table of Contents

Section 1: Summary of Legislative Reporting Requirements

The report in Section 3 fulfills the legislative reporting requirements pursuant to MCL 333.17744d (6), in which the Department of Licensing and Regulatory Affairs (LARA) is required to report the following information regarding the administration of auto-injectable epinephrine by authorized entities:

- *An authorized entity shall submit to the department, on a form prescribed by the department, a report of each incident on the premises of or in connection with the conduct of the business or activity of the authorized entity that involves the administration of auto-injectable epinephrine. The department shall annually publish a report that summarizes and analyzes all reports submitted to it under this subsection.*

Pursuant to statute, this report has been prepared to meet the annual reporting requirement. In addition, this report is also online under the following locations:

- The Bureau of Professional Licensing (BPL) website at: www.michigan.gov/bpl.
- The All About LARA Section – Legislative Reports of the Department of Licensing and Regulatory Affairs website at: www.michigan.gov/lara.

Section 2: Background

Public Act 221 of 2015, which went into effect on March 16, 2016, allows physicians to prescribe auto-injectable epinephrine to the following authorized entities: public and private schools, recreation camps, youth sports leagues, amusement parks, religious institutions, sports arenas, and other locations where allergens causing anaphylaxis may be present. An authorized entity that administers an epinephrine injector to an individual experiencing anaphylaxis, must submit to LARA a completed *Report on the Administration of Auto-Injectable Epinephrine* for each incident involving the administration of auto-injectable epinephrine on the premises of or in connection with the conduct of the business or activity of the authorized entity.

Section 3: Auto-Injectable Epinephrine Report

From March 16, 2016 to December 31, 2016, LARA received one completed *Report on the Administration of Auto-Injectable Epinephrine*. The completed report detailed an anaphylaxis event at Lake Ann Camp, in Lake Ann, Michigan, that occurred on August 16, 2016. During the event, a 21 year-old employee, with no known bee sting allergy, was stung by a bee. Following the bee sting, the employee exhibited the following symptoms: difficulty swallowing and breathing, facial swelling, wide-spread hives, chest pain, and nausea. A camp nurse, licensed as a Registered Nurse (RN), evaluated the employee, administered a stock epi-pen within 15 minutes of the bee sting, called 911, and had the individual transported to the emergency room by ambulance.